logo-loader
Retail & consumerMedia
Sure Ventures

Sure Ventures expands portfolio into holography and advertising platform

'Both VividQ and Admix offer new, innovative and impressive technologies in the VR/AR vertical'

VR pod
Immotion is one of Sure's direct investments

Virtual and augmented reality technology investor Sure Ventures PLC (LON:SURE) added stakes in a holographic company and advertising platform to its portfolio over the past three months.

VividQ is a deep tech business specialising in software designed to trigger mass adoption of 3D holography, while Admix enables AR/VR developers to monetise their content.

Sure Ventures made a direct investment in VividQ, with the funding round led by 22.1%-owned associate Suir Valley.

Both VividQ and Admix offer new, innovative and impressive technologies in the VR/AR vertical, said Gareth Burchell, director.

Sure’s net asset value dropped by 9.5% to 83.03p over the quarter to March largely due to a dip in the share price of London-listed out-of-home VR group Immotion Plc (LON:IMMO), though it recovered some ground in April.

VR game studio WarDucks, another Suir Valley investment, raised €3.3mln during the period, which represented a four-fold value uplift said Burchell.

Quick facts: Sure Ventures

Price: £1.03

Market: LSE
Market Cap: £4.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sure Ventures named herein, including the promotion by the Company of Sure Ventures in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: hVIVO’s mosquito vaccine moves into the clinic

Headlines from the Proactive Investors UK newsroom.  Clinical services group hVIVO’s (LON:HVO) experimental vaccine AGS-v PLUS is to undergo a phase 1 safety trial at the University of Maryland school of medicine. The vaccine is designed to protect against mosquito-borne diseases such as...

on 07/31/2019

2 min read